Skip to main content
OpenTrials
Completed

NCT Number: NCT02901977

Doxazosin and Ramipril in Hypertension

Randomized double-blind parallel group study in patients with mild-to-moderate hypertension to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks with ramipril or doxazosin on hemostatic mechanisms and on endothelial function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory

Stockholm, SE-182 88, Sweden

About this study

This study aims to answer the following questions: 1) Does antihypertensive therapy with doxazosin exhibit antithrombotic effects in patients with essential hypertension? 2) Are the potential antithrombotic effects of doxazosin different to the effects of an ACE inhibitor? 3) Is there a relation between the antihypertensive effect and the antithrombotic effect of these antihypertensive agents?

The co-primary outcomes are changes in endothelial function assessed by flow mediated vasodilatation, and in haemostatic function measured by the generation of thrombin-antithrombin complex.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary mild-to-moderate hypertension

Exclusion criteria

  • Pregnancy and lactation
  • Recent (6 months) malignant disease or ongoing treatment for malignancy
  • No absolute indication or contraindication for any of the study drugs

Treatment and study plan

Ramipril

Drug

Antihypertensive therapy

Other names: Tiratec

Doxazosin

Drug

Antihypertensive therapy

Other names: Alfadil ,Cardura

Primary outcomes

  1. Thrombin generation

    Time frame: 12 weeks

    Thrombin-Antithrombin complex (TAT)

  2. Endothelial function

    Time frame: 12 weeks

    Forearm post-ischemic flow mediated dilatation

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Official study title

On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension

Acronym: DoRa

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Sep 15, 2016
Registry last updated
Mar 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.